These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21854519)

  • 1. The USA Food and Drug Administration (FDA) does urological research a favour?
    Wyllie MG
    BJU Int; 2011 Sep; 108(5):E157-8. PubMed ID: 21854519
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA issues concerning conflicts of interest.
    Kurt TL
    IRB; 1990; 12(5):6-9. PubMed ID: 11654003
    [No Abstract]   [Full Text] [Related]  

  • 3. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
    Weiskopf RB;
    Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug firms back-pedal on direct advertising.
    Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA finalizing policy statement on industry-supported activities.
    Am J Hosp Pharm; 1993 Mar; 50(3):391. PubMed ID: 8442443
    [No Abstract]   [Full Text] [Related]  

  • 7. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 8. Journal supplements, libraries, and the FDA.
    Caelleigh AS
    Bull Med Libr Assoc; 1993 Apr; 81(2):237-9. PubMed ID: 8472012
    [No Abstract]   [Full Text] [Related]  

  • 9. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 10. Corporate compliance programs for FDA-regulated companies: incentives for their development and the impact of the federal sentencing guidelines for organizations.
    Freyer DH
    Food Drug Law J; 1996; 51(2):225-42. PubMed ID: 11820200
    [No Abstract]   [Full Text] [Related]  

  • 11. Food and Drug Administration proposed testing guidelines for reproduction studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
    Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
    Regul Toxicol Pharmacol; 1999 Aug; 30(1):29-38. PubMed ID: 10464044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA revamps committee conflict-of-interest rules.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
    [No Abstract]   [Full Text] [Related]  

  • 14. Industry and medicine: conflicting interests and the power of money.
    Popovsky MA; Garcia N
    Transfusion; 2007 Jun; 47(6):1098-9. PubMed ID: 17524103
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical research: outlook from industry.
    Echols R
    Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
    [No Abstract]   [Full Text] [Related]  

  • 16. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Dr. Schmidt.
    Schmidt TA
    Acad Emerg Med; 2007 Apr; 14(4):e59-62. PubMed ID: 17331913
    [No Abstract]   [Full Text] [Related]  

  • 18. Financial conflict of interest in medical research: overview and analysis of federal and state controls.
    Henderson JA; Smith JJ
    Food Drug Law J; 2002; 57(3):445-56. PubMed ID: 12710405
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is urological research stalled or stopped?
    Wyllie MG
    Curr Opin Investig Drugs; 2009 Jan; 10(1):20-2. PubMed ID: 19127483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.